Skip to main content

Femoral Arteriotomy Closure

0
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Essential Pharmaceuticals
6 programs
CE-marked MANTA vascular closure deviceN/A1 trial
MANTA Vascular Closure DeviceN/A1 trial
MANTA Vascular Closure DeviceN/A
MANTA Vascular Closure DeviceN/A
MANTA vascular closure deviceN/A1 trial
+1 more programs
Active Trials
NCT03330002Completed500Est. Feb 2021
NCT02521948Completed50Est. May 2016
NCT02908880Completed263Est. Dec 2017
+1 more trials
Teleflex Medical
Teleflex MedicalAustralia - Mascot
2 programs
MANTA Vascular Closure DeviceN/A1 trial
MANTA Vascular Closure DeviceN/A1 trial
Active Trials
NCT05142566Terminated17Est. Jan 2023
NCT05936996Completed258Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Teleflex MedicalMANTA Vascular Closure Device
Teleflex MedicalMANTA Vascular Closure Device
Essential PharmaceuticalsCE-marked MANTA vascular closure device
Essential PharmaceuticalsMANTA vascular closure device
Essential PharmaceuticalsMANTA Vascular Closure Device
Essential PharmaceuticalsX-Seal 6F Vascular Closure Device

Clinical Trials (6)

Total enrollment: 1,135 patients across 6 trials

NCT05936996Teleflex MedicalMANTA Vascular Closure Device

Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

Start: Nov 2023Est. completion: Oct 2025258 patients
N/ACompleted
NCT05142566Teleflex MedicalMANTA Vascular Closure Device

MANTA Ultrasound Closure Study

Start: Aug 2022Est. completion: Jan 202317 patients
N/ATerminated
NCT03330002Essential PharmaceuticalsCE-marked MANTA vascular closure device

MANTA Registry for Vascular Large-bore Closure

Start: Feb 2018Est. completion: Feb 2021500 patients
N/ACompleted
NCT02908880Essential PharmaceuticalsMANTA vascular closure device

MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study

Start: Dec 2016Est. completion: Dec 2017263 patients
N/ACompleted
NCT02521948Essential PharmaceuticalsMANTA Vascular Closure Device

Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device

Start: Jul 2015Est. completion: May 201650 patients
N/ACompleted
NCT02406612Essential PharmaceuticalsX-Seal 6F Vascular Closure Device

X-Seal EU Post-Market Clinical Follow-Up Protocol

Start: Apr 2015Est. completion: Jun 201647 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.